BOD Science acquisition news

BOD Science (ASX: BOD) has announced the signing of a binding share purchase agreement to acquire Biortica Agrimed Ltd. This strategic acquisition will see Biortica become a wholly-owned subsidiary of BOD Science through the issuance of ordinary shares. The deal, part of a 'Backdoor Listing', requires shareholder approval and compliance with ASX Listing Rules, with expectations to conclude by early 2025.

Acquisition summary and outlook

BOD Science Limited has taken a significant step by agreeing to acquire Biortica Agrimed Ltd, a tech-enabled horticultural business specializing in cannabis genetics and cultivation. This acquisition aims to leverage Biortica's expertise, enhancing BOD Science's position in the medical cannabis market. The transaction involves converting Biortica's preference shares and convertible notes into BOD Science's ordinary shares. This move is considered a 'Backdoor Listing,' requiring BOD Science to re-comply with the ASX Listing Rules and seek shareholder approval. The acquisition is anticipated to be completed by early 2025, following regulatory compliance and approval at the Annual General Meeting. Post-acquisition, BOD Science plans a capital raise and a name change to Biortica Agrimed Ltd, with new directors joining the board. The acquisition aligns with BOD Science's strategy to expand its footprint in the cannabis industry by integrating Biortica's advanced genetic and cultivation capabilities.

Executive commentary on acquisition

The acquisition of Biortica Agrimed Ltd positions us as a leader in the medical cannabis market. With Biortica's expertise in high-tech cultivation and genetics, we aim to enhance our product offerings and expand our operations significantly.